SEER
Seer, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.94
−2.51%Oct 29, 2026, 20:30 UTC
Seer announced that its Special Committee concluded its review and rejected recent acquisition proposals, leaving Seer to remain an independent public company.
Source:Oct 21, 2026, 20:05 UTC
Seer announced that it will report its third-quarter 2026 financial results on November 10, 2026, with a webcast conference call scheduled for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).
Source:Sep 23, 2026, 11:00 UTC
Seer, Inc. announced that researchers from Nanyang Technological University will present early findings from the PRECISE-SG100K proteomics study at the 2026 HUPO World Congress in Singapore.
Source:Sep 18, 2026, 20:13 UTC
David Horn resigned as President, Chief Financial Officer and Treasurer of Seer, Inc., effective October 1, 2026.
Source:Sep 18, 2026, 20:13 UTC
Seer, Inc. appointed Charles Endweiss as Treasurer and principal financial and accounting officer, effective October 1, 2026.
Sep 18, 2026, 20:13 UTC
Seer, Inc. appointed Omid Farokhzad as President, effective October 1, 2026.
Aug 11, 2026, 20:05 UTC
Seer, Inc. announced its financial results for the second quarter ended June 30, 2026.
Jul 28, 2026, 16:47 UTC
Bradley L. Radoff and Michael Torok, owning about 7.7% of Seer, Inc., submitted a non-binding proposal to acquire Seer for $2.55 per share in cash plus a contingent value right.
Jul 6, 2026, 10:50 UTC
Seer's CEO submitted a buyout proposal for the company.
Source:Jul 2, 2026, 21:00 UTC
Seer, Inc. received an unsolicited acquisition proposal from Omid Farokhzad, M.D.
Source: